{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:43:56Z","timestamp":1774536236013,"version":"3.50.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>Two randomized controlled trials (RCTs), Mitra-Fr and Coapt, evaluating the benefit of percutaneous repair (PR) for heart failure (HF) patients with severe mitral regurgitation, have led to conflicting results. We aimed to evaluate the impact of these trial results on the cost-effectiveness of PR using effectiveness inputs from the two RCTs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We developed a time varying Markov type model with three mutually exclusive health states: alive without HF hospitalisation, alive with HF hospitalisation, and dead. Clinically plausible extrapolations beyond observed data were obtained by developing parametric modelling for overall survival and HF hospitalisations using published data from each trial. We adopted the perspective of the French Health System and used a 30-year time horizon. Results were expressed as \u20ac \/ quality-adjusted life year (QALY) gained using utility inputs from literature.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Findings<\/jats:title>\n<jats:p>Results are presented using treatment efficacy measures from Mitra-F and Coapt trials respectively. With the Mitra-Fr data, after annual discounting, the base case model generated an incremental 0.00387 QALY at a cost of \u20ac25,010, yielding an incremental cost effectiveness ratio (ICER) of \u20ac6,467,032 \/ QALY. The model was sensitive to changes made to model inputs. There was no potential of PR being cost-effective.<\/jats:p>\n<jats:p>With the Coapt data, the model generated 1.19 QALY gain at a cost of \u20ac26,130 yielding an ICER of \u20ac21,918 \/ QALY and at a threshold of &gt;\u20ac50,000\/QALY PR had a probability of 1 of being cost-effective.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Implications<\/jats:title>\n<jats:p>Cost effectiveness results were conflicting; reconciling differences between trials is a priority and could promote optimal cost effectiveness analyses and resource allocation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0241361","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:47:55Z","timestamp":1604947675000},"page":"e0241361","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Conflicting findings between the Mitra-Fr and the Coapt trials: Implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-0453","authenticated-orcid":true,"given":"Xavier","family":"Armoiry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1644-9542","authenticated-orcid":true,"given":"Jean-Fran\u00e7ois","family":"Obadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Auguste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5353-9988","authenticated-orcid":true,"given":"Martin","family":"Connock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"pone.0241361.ref001","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.jtcvs.2018.07.017","article-title":"Innovative valve disease therapies, a potential benefit for patients but calling for more clinical evaluation","volume":"156","author":"X Armoiry","year":"2018","journal-title":"The Journal of Thoracic and Cardiovascular Surgery"},{"key":"pone.0241361.ref002","doi-asserted-by":"crossref","first-page":"S1949","DOI":"10.21037\/jtd.2018.04.154","article-title":"Transcatheter Mitral Valve Replacement: slow and steady progress","volume":"10","author":"DWM Muller","year":"2018","journal-title":"J Thorac Dis"},{"key":"pone.0241361.ref003","article-title":"More than 100,000 MitraClips have been implanted","author":"GW Stone","journal-title":"Who knows who did the first MitraClip procedure?"},{"key":"pone.0241361.ref004","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","article-title":"Percutaneous Repair or Surgery for Mitral Regurgitation","volume":"364","author":"T Feldman","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0241361.ref005","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacc.2013.02.094","article-title":"Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe","volume":"62","author":"F Maisano","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"pone.0241361.ref006","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurjhf\/hfs079","article-title":"MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry","volume":"14","author":"S Baldus","year":"2012","journal-title":"European Journal of Heart Failure"},{"key":"pone.0241361.ref007","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"H Baumgartner","year":"2017","journal-title":"European Heart Journal"},{"key":"pone.0241361.ref008","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation","volume":"379","author":"J-F Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0241361.ref009","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter Mitral-Valve Repair in Patients with Heart Failure","volume":"379","author":"GW Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0241361.ref010","first-page":"ejhf.1616","article-title":"Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation: Outcomes at 2 years","author":"B Iung","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"pone.0241361.ref011","first-page":"CIRCULATIONAHA.119.043275","article-title":"Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial","author":"SJ Baron","year":"2019","journal-title":"Circulation"},{"key":"pone.0241361.ref012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijcard.2016.01.212","article-title":"Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation","volume":"209","author":"P Armeni","year":"2016","journal-title":"Int J Cardiol"},{"key":"pone.0241361.ref013","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40273-018-0755-x","article-title":"Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review","volume":"37","author":"GL Di Tanna","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"pone.0241361.ref014","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1136\/heartjnl-2013-304598","article-title":"The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective","volume":"100","author":"A Griffiths","year":"2014","journal-title":"Heart"},{"key":"pone.0241361.ref015","doi-asserted-by":"crossref","first-page":"e13124","DOI":"10.1111\/ctr.13124","article-title":"Cost-utility analysis of direct ventricular assist device vs double bridges to heart transplantation in patients with refractory heart failure","volume":"31","author":"H-H Chang","year":"2017","journal-title":"Clin Transplant"},{"key":"pone.0241361.ref016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"P Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"pone.0241361.ref017","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v053.i12","article-title":"stgenreg: A Stata Package for General Parametric Survival Analysis","volume":"53","author":"MJ Crowther","year":"2013","journal-title":"J Stat Soft"},{"key":"pone.0241361.ref018","unstructured":"Avis relatif \u00e0 la tarification de MITRACLIP et MITRACLIP NT vis\u00e9s \u00e0 l\u2019article L. 165\u20131 du code de la s\u00e9curit\u00e9 sociale."},{"key":"pone.0241361.ref019","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ehf2.12432","article-title":"Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France","volume":"6","author":"S Bourguignon","year":"2019","journal-title":"ESC Heart Fail"},{"key":"pone.0241361.ref020","unstructured":"Nomenclatures: NGAP et LPP. [cited 4 Nov 2019]. Available: https:\/\/www.ameli.fr\/infirmier\/exercice-liberal\/facturation-remuneration\/nomenclatures-ngap-lpp\/nomenclatures-ngap-lpp"},{"key":"pone.0241361.ref021","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Guide M\u00e9thodologique: Choix m\u00e9thodologiques pour l\u2019\u00e9valuation de l\u2019efficience \u00e0 la HAS Version soumise \u00e0 la consultation publique. 2019."},{"key":"pone.0241361.ref022","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.3747\/co.19.946","article-title":"International variability in the reimbursement of cancer drugs by publically funded drug programs","volume":"19","author":"PK Cheema","year":"2012","journal-title":"Curr Oncol"},{"key":"pone.0241361.ref023","doi-asserted-by":"crossref","first-page":"A490","DOI":"10.1016\/j.jval.2016.09.830","article-title":"Is There a Threshold in France?: First Exhaustive Review of Published Health-Economic Appraisals by the Haute Autorite De Sante (HAS), (French National Authority for Health)","volume":"19","author":"C Cartier-Bechu","year":"2016","journal-title":"Value in Health"},{"key":"pone.0241361.ref024","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1536867X1801800114","article-title":"Assessing the Health Economic Agreement of Different Data Sources","volume":"18","author":"D Gallacher","year":"2018","journal-title":"The Stata Journal"},{"key":"pone.0241361.ref025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1536867X0400400302","article-title":"Graphing Confidence Ellipses: An Update of Ellip for Stata 8","volume":"4","author":"A. Alexandersson","year":"2004","journal-title":"The Stata Journal"},{"key":"pone.0241361.ref026","article-title":"COAPT Three-Year Outcomes from a Randomized Trial of Transcatheter Mitral Valve Leaflet Approximation in Patients with Heart Failure and Secondary Mitral Regurgitation","author":"MJ Mack","year":"2019","journal-title":"TCT"},{"key":"pone.0241361.ref027","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijcard.2013.12.015","article-title":"Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program","volume":"171","author":"A Clarke","year":"2014","journal-title":"Int J Cardiol"},{"key":"pone.0241361.ref028","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ehf2.12194","article-title":"Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database","volume":"5","author":"A Tadmouri","year":"2018","journal-title":"ESC Heart Fail"},{"key":"pone.0241361.ref029","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.healun.2014.01.003","article-title":"Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service bridge-to-transplant program for patients with heart failure","volume":"33","author":"R Pulikottil-Jacob","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"pone.0241361.ref030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jcmg.2018.11.006","article-title":"Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials","volume":"12","author":"PA Grayburn","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"pone.0241361.ref031","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1161\/CIRCULATIONAHA.118.038207","article-title":"Treatment of Functional Mitral Regurgitation","volume":"139","author":"M Enriquez-Sarano","year":"2019","journal-title":"Circulation"},{"key":"pone.0241361.ref032","article-title":"Mitral regurgitation in heart failure: time for a rethink","author":"F Praz","year":"2019","journal-title":"Eur Heart J"},{"key":"pone.0241361.ref033","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1056\/NEJMe1812279","article-title":"Percutaneous Repair of Secondary Mitral Regurgitation\u2014A Tale of Two Trials","volume":"379","author":"RA Nishimura","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0241361.ref034","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2019.05.015","article-title":"Prognostic impact of MitraClip in patients with left ventricular dysfunction and functional mitral valve regurgitation: A comprehensive meta-analysis of RCTs and adjusted observational studies","volume":"290","author":"M Bertaina","year":"2019","journal-title":"International Journal of Cardiology"},{"key":"pone.0241361.ref035","doi-asserted-by":"crossref","first-page":"A340","DOI":"10.1016\/j.jval.2015.09.141","article-title":"Survival and Rehospitalization After a First Hospitalization for Heart Failure: a Nationwide Population-Based Cohort Study using the French Egb Database","volume":"18","author":"C Bonnet","year":"2015","journal-title":"Value in Health"},{"key":"pone.0241361.ref036","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: population based cohort study","author":"CJ Taylor","year":"2019","journal-title":"BMJ"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:48:15Z","timestamp":1604947695000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241361"}},"subtitle":[],"editor":[{"given":"Bart","family":"Ferket","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241361","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}